Defibrotide sodium –

Severe Veno-Occlusive Disease (VOD) 

Molecular Name: Defibrotide Sodium

Active Ingredient: Defibrotide

Strength: 80 mg/mL (mg per milliliter)

1.Sodium benzoate
2.Sodium hydroxide
3.Hydrochloric acid (for pH adjustment)
4.Water for injection

Defibrotide sodium is an innovative pharmaceutical solution meticulously crafted to address the critical medical need of treating severe veno-occlusive disease (VOD) in patients undergoing haematopoietic (blood) stem cell transplantation. Designed with precision and adhering to stringent quality standards, Defibrotide sodium offers a specialized approach to providing effective relief and support for individuals grappling with this challenging medical condition.

Special Storage Precautions: Defibrotide sodium should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F). It should be protected from light and freezing. The vials should not be shaken vigorously. It’s important to follow the storage instructions provided by the manufacturer and the healthcare provider.

Key Features:

· VOD Targeting: Defibrotide sodium’s formulation is uniquely tailored to target and alleviate severe veno-occlusive disease (VOD) that can develop in patients undergoing haematopoietic stem cell transplantation.

· Scientifically Developed: Crafted through rigorous research and medical expertise, Defibrotide sodium’s formulation is optimized to cater to the distinct requirements of VOD patients.

· Evidence-Based Relief: Defibrotide sodium draws strength from clinical studies and medical research, delivering evidence-based relief to patients navigating the complexities of VOD.

· Expert Endorsement: Healthcare professionals specializing in haematopoietic stem cell transplantation endorse Defibrotide sodium, underscoring its credibility and reliability.


· Active Ingredients: Defibrotide sodium comprises a proprietary blend of meticulously selected active components, thoughtfully chosen to address the specific challenges posed by severe veno-occlusive disease (VOD).

· Dosage: The recommended dosage of Defibrotide sodium is determined based on the severity of the condition and the unique needs of each patient, as guided by a qualified healthcare provider.

· Packaging: Defibrotide sodium is thoughtfully packaged to safeguard the integrity of its specialized formulation and ensure convenient administration.

Usage Guidelines:

1. Medical Consultation: Initiating Defibrotide sodium treatment necessitates consultation with a qualified healthcare provider well-versed in haematopoietic stem cell transplantation and VOD.

2. Dosage Adherence: Adherence to the prescribed dosage and administration instructions, as provided by your healthcare provider, is essential for optimal results.

3. Monitoring: Regularly monitoring your response to Defibrotide sodium is vital. Any changes or concerns should be promptly communicated to your healthcare provider for ongoing assessment and adjustment.

Disclaimer: The information presented on this product page is intended solely for educational and informational purposes. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding your specific medical condition and treatment options.

Usage Guidelines: The guidelines outlined here are general recommendations and may be subject to adjustment based on individual patient circumstances and medical advice. Adhering to your healthcare provider’s guidance is imperative for the safe and effective use of Defibrotide sodium in treating severe veno-occlusive disease (VOD) during haematopoietic stem cell transplantation.


 Individuals with a known hypersensitivity to any of Defibrotide sodium’s ingredients should avoid its use. Pregnant or breastfeeding individuals should also consult a healthcare professional before considering Defibrotide sodium.

Defibrotide sodium should be stored in a cool, dry environment at controlled room temperature. It must be kept out of reach of children and pets, and protected from excessive heat or moisture.

Defibrotide sodium has exhibited promising efficacy in treating severe veno-occlusive disease (VOD) among patients undergoing haematopoietic stem cell transplantation. Clinical studies have demonstrated its potential to alleviate symptoms and enhance patient outcomes, though individual responses may vary.

  1. Defibrotide sodium is typically administered under the supervision of a healthcare professional. The appropriate dosage and administration regimen are determined by the severity of the VOD and the patient’s overall health. Adherence to your healthcare provider’s instructions is crucial.

Common side effects of Defibrotide sodium may include nausea, vomiting, diarrhea, abdominal pain, headache, and fever. While serious allergic reactions are rare, they are possible. It is imperative to promptly report any unusual or severe symptoms to your healthcare provider.